Skip to main content
Clinical Trials/NCT00040326
NCT00040326
Completed
Phase 3

Early Randomized Surgical Epilepsy Trial

University of California, Los Angeles12 sites in 1 country200 target enrollmentJuly 2002

Overview

Phase
Phase 3
Intervention
anteromesial temporal resection
Conditions
Epilepsy
Sponsor
University of California, Los Angeles
Enrollment
200
Locations
12
Primary Endpoint
The primary outcome measure will be freedom from disabling epileptic seizures (complex partial and secondarily generalized seizures, and simple partial seizures that are apparent to an observer)
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this trial is to compare the effectiveness of early surgical intervention for mesial temporal lobe epilepsy to continued treatment with antiepileptic drugs.

Detailed Description

Mesial temporal lobe epilepsy (MTLE) is the most common form of epilepsy, and the most medically intractable. An estimated one-quarter to one-half of the 400,000 patients in the United States with intractable epilepsy have MTLE. Generally, MTLE becomes intractable in adolescence and early adulthood. Persistence of seizures during this time commonly causes adverse social and psychological consequences which can become irreversible. The current treatment of MTLE primarily consists of medications to control seizures. Usually surgical treatment is considered only if medications are not effective. Recent studies have shown that surgery can stop disabling seizures in 60 to 70% of patients with long standing MTLE. However, to date, no research study has examined surgery performed as an early therapy. The goal of the study is to determine if more patients treated with early surgery become seizure free and have improved quality of life compared to similar patients who continue to receive antiepileptic medication only. This study will determine the difference in seizure frequency between the two groups and the impact of the two treatments on the quality of life of the participants.

Registry
clinicaltrials.gov
Start Date
July 2002
End Date
November 2007
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

1

anteromesial temporal resection

Intervention: anteromesial temporal resection

2

antiepileptic drugs

Intervention: antiepileptic drugs

Outcomes

Primary Outcomes

The primary outcome measure will be freedom from disabling epileptic seizures (complex partial and secondarily generalized seizures, and simple partial seizures that are apparent to an observer)

Time Frame: 2 years

Study Sites (12)

Loading locations...

Similar Trials